Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
| Autor: | Joe D Strain, James R Clem, Debra K Farver |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Statin medicine.drug_class Disease Review chemistry.chemical_compound Internal medicine medicine Dosing Adverse effect LDL-C Cause of death Cholesterol business.industry lcsh:Public aspects of medicine Health Policy Public Health Environmental and Occupational Health Type 2 Diabetes Mellitus lcsh:RA1-1270 Clinical trial stomatognathic diseases chemistry statin therapy lipids (amino acids peptides and proteins) treatment goals business |
| Zdroj: | Risk Management and Healthcare Policy Risk Management and Healthcare Policy, Vol 2010, Iss default, Pp 1-11 (2009) |
| ISSN: | 1179-1594 |
| Popis: | James R Clem1, Joe D Strain2, Debra K Farver31South Dakota State University College of Pharmacy Sioux Falls, South Dakota, USA; 2South Dakota State University College of Pharmacy, Rapid City Regional Hospital, Rapid City, South Dakota, USA; 3South Dakota State University College of Pharmacy, Yankton, South Dakota, USAAbstract: Cardiovascular disease remains the leading cause of death in the world. A significant amount of clinical data are available to demonstrate the positive influence that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has on slowing the progression of cardiovascular disease and improving clinical outcomes. Achieving the treatment goals for cholesterol in cardiovascular disease continues to present challenges. Recent clinical trial information is available assessing the use of more aggressive initial doses of statin therapy based on initial low-density lipoprotein cholesterol (LDL-C) measurements in an attempt to reach treatment goals sooner. Six clinical trials assessed low-, moderate- and high-risk individuals as well as those with type 2 diabetes mellitus to determine if this treatment approach is both safe and effective. The studies concluded that initial dosing of statin therapy determined by a baseline LDL-C measurement demonstrates good achievement in reaching treatment goals and does not result in a higher rate of adverse effects.Keywords: LDL-C, statin therapy, treatment goals |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|